Loading...
•
Mar 31, 2024
Enfusion Q1 2024 Earnings Report
Enfusion started the year with excellent results, positioning the company to execute on its 2024 targets.
Key Takeaways
Enfusion reported a strong start to 2024 with revenue growth of 17.3% year-over-year. The company saw an increase in new client wins and expanded its presence in Europe and Scandinavia. Average Contract Value increased sequentially. However, they reported a net loss of $0.761 million
First quarter revenue grew 17.3% year-over-year, with revenue growth accelerating 255 basis points sequentially.
Adjusted EBITDA margin expanded significantly compared to the same period last year.
33 new client wins in the first quarter, up from 27 in 1Q23, with deeper penetration across geographies.
Average Contract Value increased from $219,000 to $226,000 sequentially, representing 3.2% quarter-over-quarter growth and 7.8% year-over-year growth.
Revenue by Segment
Forward Guidance
Enfusion is on track to becoming a Rule of 40 company over the medium term and is modulating growth and profitability to sustain investments for future growth consistent with medium-term targets.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...